Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Delforge

Showing results (1-10 of 188) with videos related to

Pageof 19
Sort By:
Expert Opinion on Pharmacotherapy|September 28, 2011
Bortezomib for previously untreated multiple myelomaMichel Delforge
The Hematology Journal : the Official Journal of the European Haematology Association|September 23, 2003
Understanding the pathogenesis of myelodysplastic syndromesMichel Delforge
Blood|March 10, 2017
How I manage the toxicities of myeloma drugsMichel Delforge, Heinz Ludwig
Targeted Oncology|January 21, 2026
Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What's the Current Status?Finn Segers, Michel Delforge
Journal of Geriatric Oncology|August 28, 2016
Concise review - Treatment of multiple myeloma in the very elderly: How do novel agents fit in?Nicolas Kint, Michel Delforge
Expert Review of Hematology|March 6, 2015
Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendationsHelena Maes, Michel Delforge
Blood|June 19, 2010
Threatening clots in MGUS and myelomaHeinz Ludwig, Michel Delforge
Lancet (London, England)|December 27, 2016
Multiple myeloma: new treatments gain momentumHeinz Ludwig, Michel Delforge
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|June 7, 2016
The evolving treatment paradigm of multiple myeloma: From past to present and futureMeral Beksaç, Michel Delforge, Paul Richardson
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|October 24, 2009
Current insight into thrombotic thrombocytopenic purpuraLen Verbeke, Michel Delforge, Daan Dierickx
Pageof 19

Showing results (1-10 of 188) with videos related to

Sort By:
Pageof 19
Expert Opinion on Pharmacotherapy|September 28, 2011
Bortezomib for previously untreated multiple myelomaMichel Delforge
The Hematology Journal : the Official Journal of the European Haematology Association|September 23, 2003
Understanding the pathogenesis of myelodysplastic syndromesMichel Delforge
Blood|March 10, 2017
How I manage the toxicities of myeloma drugsMichel Delforge, Heinz Ludwig
Targeted Oncology|January 21, 2026
Antibody-Drug Conjugates, T-Cell Engager Bispecific Antibodies and Chimeric Antigen Receptor T Cells for Multiple Myeloma: What's the Current Status?Finn Segers, Michel Delforge
Journal of Geriatric Oncology|August 28, 2016
Concise review - Treatment of multiple myeloma in the very elderly: How do novel agents fit in?Nicolas Kint, Michel Delforge
Expert Review of Hematology|March 6, 2015
Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendationsHelena Maes, Michel Delforge
Blood|June 19, 2010
Threatening clots in MGUS and myelomaHeinz Ludwig, Michel Delforge
Lancet (London, England)|December 27, 2016
Multiple myeloma: new treatments gain momentumHeinz Ludwig, Michel Delforge
Turkish Journal of Haematology : Official Journal of Turkish Society of Haematology|June 7, 2016
The evolving treatment paradigm of multiple myeloma: From past to present and futureMeral Beksaç, Michel Delforge, Paul Richardson
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|October 24, 2009
Current insight into thrombotic thrombocytopenic purpuraLen Verbeke, Michel Delforge, Daan Dierickx
Pageof 19